Our Values
Message
Corporate Philosophy
Corporate Branding
Sawai at a Glance
Transparency
Products
Quality Policy & Feature of Each Function
ESG Data(Related Content)
Sustainability
Sustainability Initiatives
Our Approach
ESG Data
Integrated Report(Related Content)
Our Humanistic Business
Corporate Profile
Corporate History
Investors
Message for Our Investors
Corporate Philosophy(Related Content)
Stock Information
IR News
Financials
IR Reports
IR Schedule
Integrated Report
Disclosure Policy
IR News Mailing Service
Our humanistic business
Index
Top Message
Feb. 15. 2021
Sawai Receives Approvals for Eight Generic Drugs with 20 Strengths
Feb. 12. 2021
Sawai Reports Third Quarter FY2020 Financial Results
Jan. 28. 2021
Sawai and Neurolief enter into Exclusive Development and Marketing Agreement for Relivion
Dec. 16. 2020
Upsher-Smith Launches Ramelteon Tablets
Dec. 10. 2020
Sawai Launches Two Generic Drugs with 10 Strengths
Nov. 24. 2020
Notice of Convocation of an Extraordinary General Meeting of Shareholders and the Matters to be Resolved Thereat, as well as Partial Amendments to the Articles of Incorporation
Nov. 09. 2020
Sawai Reports First Half of FY2020 Financial Results
Oct. 19. 2020
Sawai Launches Dutasteride Capsules
Oct. 06. 2020
Sawai Receives Approval for Dutasteride Capsules
Aug. 17. 2020
Sawai Receives Approvals for 4 Generic Drugs with 13 Strengths
Aug. 11. 2020
Upsher-Smith and AmbioPharm Announce Partnership Agreement to Develop and Market Corticotropin Injection
Aug. 06. 2020
Sawai Reports First Quarter FY2020 Financial Results
Jul. 28. 2020
Notice of Transition to a Holding Company Structure through Sole-Share Transfer and Establishment of the Record Date for Convocation of an Extraordinary General Meeting of Shareholders
Jul. 02. 2020
Upsher-Smith Launches Propafenone Hydrochloride Extended-Release Capsules
Jun. 25. 2020
Upsher-Smith Launches Ethacrynic Acid Tablets, USP
Jun. 23. 2020
Sawai Launches Vardenafil Tablets
Jun. 22. 2020
Sawai and Neugen Pharma enter into Co-development and Definitive License Agreement for ALS Drug
Jun. 18. 2020
Sawai Launches 14 Generic Drugs with 29 Strengths
Jun. 04. 2020
Sawai Receives Approval for Vardenafil Tablets
May. 14. 2020
Sawai Reports FY2019 Financial Results
Notice of Commencement of Preparation for Transition to a Holding Company Structure through Sole-Share Transfer
Mar. 23. 2020
Notice of Change in Representative Directors
Mar. 06. 2020
Sawai Launches Tadalafil Tablets
Feb. 20. 2020
Sawai Receives Approval for Tadalafil Tablets